Chimeric T cells for adoptive immunotherapy of cancer: Using what have we learned to plan for the future

Immunotherapy

Volumn 1, Issue 6, 2009, Pages 905-912

  Peinert, Stefan ^a   Kershaw, Michael H ^a,b   Prince, H Miles ^a  

^a PETER MACCALLUM CANCER CENTRE   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CD20 ANTIBODY; INTERLEUKIN 2; T LYMPHOCYTE RECEPTOR;

ADOPTIVE IMMUNOTHERAPY; ANTIGEN PRESENTING CELL; ANTINEOPLASTIC ACTIVITY; CANCER IMMUNOTHERAPY; DYSPNEA; EDITORIAL; FOLLICULAR LYMPHOMA; HUMAN; HYPOTENSION; IMMUNE RESPONSE; KIDNEY CARCINOMA; LOW DRUG DOSE; MELANOMA; NEUROBLASTOMA; OVARY CANCER; PRIORITY JOURNAL; T LYMPHOCYTE; THERAPY EFFECT;

ANTIGENS, CD28; ANTIGENS, CD3; ANTIGENS, NEOPLASM; CELL TRANSFORMATION, NEOPLASTIC; CLINICAL TRIALS AS TOPIC; HUMANS; IMMUNOTHERAPY, ADOPTIVE; LYMPHOCYTE ACTIVATION; NEOPLASMS; PROTEIN ENGINEERING; RECEPTORS, ANTIGEN, T-CELL; RECOMBINANT FUSION PROTEINS; SINGLE-CHAIN ANTIBODIES; T-LYMPHOCYTES;

EID: 77953413843     PISSN: 1750743X     EISSN: None     Source Type: Journal    
DOI: 10.2217/imt.09.69     Document Type: Editorial

References (48)

1. Smyth MJ, Godfrey DI, Trapani JA: A fresh look at tumor immunosurveillance and immunotherapy. Nat. Immunol. 2(4), 293-299 (2001).
2. Rosenberg SA, Fox E, Churchill WH: Spontaneous regression of hepatic metastases from gastric carcinoma. Cancer 29(2), 472-474 (1972).
3. Cole WH: Relationship of causative factors in spontaneous regression of cancer to immunologic factors possibly effective in cancer. J. Surg. Oncol. 8(5), 391-411 (1976).
4. Dudley ME, Wunderlich JR, Yang JC et al.: Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J. Clin. Oncol. 23(10), 2346-2357 (2005).
5. Dudley ME, Yang JC, Sherry R et al.: Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens. J. Clin. Oncol. 26(32), 5233-5239 (2008).
6. Morgan RA, Dudley ME, Wunderlich JR et al.: Cancer regression in patients after transfer of genetically engineered lymphocytes. Science 314(5796), 126-129 (2006).
7. 2-microglobulin in metastatic melanomas from five patients receiving immunotherapy. J. Natl Cancer Inst. 88(2), 100-108 (1996). (Pubitemid 2619238)
8. Khong HT, Restifo NP: Natural selection of tumor variants in the generation of 'tumor escape' phenotypes. Nat. Immunol. 3(11), 999-1005 (2002).
9. Thomas S, Xue SA, Cesco-Gaspere M et al.: Targeting the Wilms tumor antigen 1 by TCR gene transfer: TCR variants improve tetramer binding but not the function of gene modified human T cells. J. Immunol. 179(9), 5803-5810 (2007).
10. Haynes NM, Snook MB, Trapani JA et al.: Redirecting mouse CTL against colon carcinoma: superior signaling efficacy of single-chain variable domain chimeras containing TCR-ζ vs Fcε RI-γ. J. Immunol. 166(1), 182-187 (2001).
11. + T cell responses to influenza A virus: roles for cross-presentation and lysis-independent immunodomination. J. Immunol. 173(8), 5021-5027 (2004). (Pubitemid 39387784)
12. + tumor-reactive effector memory T cells in humans after adoptive cell transfer therapy. Blood 105(1), 241-250 (2005).
13. Acuto O, Michel F: CD28-mediated co-stimulation: a quantitative support for TCR signalling. Nat. Rev. Immunol. 3(12), 939-951 (2003).
14. + memory effector T cells reconstitutes antigen-induced IL-2 production. J. Exp. Med. 198(6), 947-955 (2003).
15. Hombach A, Wieczarkowiecz A, Marquardt T et al.: Tumor-specific T cell activation by recombinant immunoreceptors: CD3ζ signaling and CD28 costimulation are simultaneously required for efficient IL-2 secretion and can be integrated into one combined CD28/CD3ζ signaling receptor molecule. J Immunol. 167(11), 6123-6131 (2001). (Pubitemid 33081538)
16. Finney HM, Lawson ADG, Bebbington CR, Weir ANC: Chimeric receptors providing both primary and costimulatory signaling in T cells from a single gene product. J. Immunol. 161(6), 2791-2797 (1998).
17. Finney HM, Akbar AN, Lawson ADG: Activation of resting human primary T cells with chimeric receptors: costimulation from CD28, inducible costimulator, CD134, and CD137 in series with signals from the TCRζ chain. J. Immunol. 172(1), 104-113 (2004).
18. Marcu-Malina V, Van Dorp S, Kuball J: Re-targeting T-cells against cancer by gene-transfer of tumor-reactive receptors. Expert Opin. Biol. Ther. 9(5), 579-591 (2009).
19. Kershaw MH, Teng MW, Smyth MJ, Darcy PK: Supernatural T cells: genetic modification of T cells for cancer therapy. Nat. Rev. Immunol. 5(12), 928-940 (2005).
20. Brentjens RJ, Latouche JB, Santos E et al.: Eradication of systemic B-cell tumors by genetically targeted human T lymphocytes co-stimulated by CD80 and interleukin-15. Nat. Med. 9(3), 279-286 (2003).
21. Westwood JA, Smyth MJ, Teng MWL et al.: Adoptive transfer of T cells modified with a humanized chimeric receptor gene inhibits growth of Lewis-Y-expressing tumors in mice. Proc. Natl Acad. Sci. USA 102(52), 19051-19056 (2005).
22. Vera J, Savoldo B, Vigouroux S et al.: T lymphocytes redirected against the κ light chain of human immunoglobulin efficiently kill mature B lymphocyte-derived malignant cells. Blood 108(12), 3890-3897 (2006). (Pubitemid 44864573)
23. Gade TPF, Hassen W, Santos E et al.: Targeted elimination of prostate cancer by genetically directed human T lymphocytes. Cancer Res. 65(19), 9080-9088 (2005). (Pubitemid 41377401)
24. Kershaw MH, Jackson JT, Haynes NM et al.: Gene-engineered T cells as a superior adjuvant therapy for metastatic cancer. J. Immunol. 173(3), 2143-2150 (2004).
25. Haynes NM, Trapani JA, Teng MW et al.: Rejection of syngeneic colon carcinoma by CTLs expressing single-chain antibody receptors codelivering CD28 costimulation. J. Immunol. 169(10), 5780-5786 (2002).
26. Kershaw MH, Westwood JA, Parker LL et al.: A Phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer. Clin. Cancer Res. 12(20), 6106-6115 (2006).
27. Till BG, Jensen MC, Wang J et al.: Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells. Blood 112(6) 2261-2271 (2008).
28. Lamers CHJ, Sleijfer S, Vulto AG et al.: Treatment of metastatic renal cell carcinoma with autologous T lymphocytes genetically retargeted against carbonic anhydrase IX: first clinical experience. J. Clin. Oncol. 24(13), E20-E22 (2006).
29. Park JR, Digiusto DL, Slovak M et al.: Adoptive transfer of chimeric antigen receptor re-directed cytolytic T lymphocyte clones in patients with neuroblastoma. Mol. Ther. 15(4), 825-833 (2007).
30. Pule MA, Savoldo B, Myers GD et al.: Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma. Nat. Med. 14(11), 1264-1270 (2008).
31. Leen AM, Myers GD, Sili U et al.: Monoculture-derived T lymphocytes specific for multiple viruses expand and produce clinically relevant effects in immunocompromised individuals. Nat. Med. 12(10), 1160-1166 (2006).
32. Hacein-Bey-Abina S, Von Kalle C, Schmidt M et al.: A serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency. N. Engl. J. Med. 348(3), 255-256. (2003).
33. Newrzela S, Cornils K, Li Z et al.: Resistance of mature T cells to oncogene transformation. Blood 112(6), 2278-2286 (2008).
34. Donahue R, Kessler S, Bodine D et al.: Helper virus induced T cell lymphoma in nonhuman primates after retroviral mediated gene transfer. J. Exp. Med. 176(4), 1125-1135 (1992).
35. Markowitz D, Hesdorffer C, Ward M, Goff S, Bank A: Retroviral gene transfer using safe and efficient packaging cell lines. Ann. N. Y. Acad. Sci. 612(407), 407-414 (1990).
36. Eckert HG, Kuhlcke K, Schilz AJ et al.: Clinical scale production of an improved retroviral vector expressing the human multidrug resistance 1 gene (MDR1). Bone Marrow Transplant 25 (Suppl. 2), S114-S117 (2000).
37. Westwood JA, Murray WK, Trivett M et al.: Absence of retroviral vector-mediated transformation of gene-modified T cells after long-term engraftment in mice. Gene Ther. 15(14), 1056-1066 (2008). (Pubitemid 351927696)
38. Deeks SG, Wagner B, Anton PA et al.: A Phase II randomized study of HIV-specific T-cell gene therapy in subjects with undetectable plasma viremia on combination antiretroviral therapy. Mol. Ther. 5(6), 788-797 (2002).
39. Ahmad M, Rees RC, Ali SA: Escape from immunotherapy: possible mechanisms that influence tumor regression/progression. Cancer Immunol. Immunother. 53(10), 844-854 (2004).
40. Zeis M, Uharek L, Glass B et al.: Eradication of residual disease by administration of leukemia-specific T cells after experimental allogeneic bone marrow transplantation. Exp. Hematol. 26(11), 1068-1073 (1998).
41. Schmid C, Labopin M, Nagler A et al.: Donor lymphocyte infusion in the treatment of first hematological relapse after allogeneic stem-cell transplantation in adults with acute myeloid leukemia: a retrospective risk factors analysis and comparison with other strategies by the EBMT Acute Leukemia Working Party. J. Clin. Oncol. 25(31), 4938-4945 (2007).
42. + T-cell memory in tumor immunology and immunotherapy. Immunol. Rev. 211(1), 214-224 (2006).
43. Berger C, Jensen MC, Lansdorp PM, Gough M, Elliott C, Riddell SR: Adoptive transfer of effector CD8 T cells derived from central memory cells establishes persistent T-cell memory in primates. J. Clin. Invest. 118(1), 294-305 (2008).
44. + T cells undergo functional polarization to effector and central memory cells in response to antigen exposure. ASH Annual Meeting Abstracts 112(11) (2008) (Abstract 1531).
45. Kaneko S, Mastaglio S, Bondanza A et al.: IL-7 and IL-15 allow the generation of suicide gene-modified alloreactive self-renewing central memory human T lymphocytes. Blood 113(5), 1006-1015 (2009).
46. + T cells for adoptive immunotherapy. Blood 111(11), 5326-5333 (2008).
47. + T cells via TLR4 signaling. J. Clin. Invest. 117(8), 2197-2204 (2007).
48. Klebanoff CA, Khong HT, Antony PA, Palmer DC, Restifo NP: Sinks, suppressors and antigen presenters: how lymphodepletion enhances T cell-mediated tumor immunotherapy. Trends Immunol. 26(2), 111-117 (2005).